ABSTRACT
In addition to standard postmarketing drug safety monitoring, Section 915 of the Food and Drug Administration Amendments Act of 2007 (FDAAA) requires the US Food and Drug Administration (FDA) to conduct a summary analysis of adverse event reports to identify risks of a drug or biologic product 18 months after product approval, or after 10,000 patients have used the product, whichever is later. We assessed the extent to which these analyses identified new safety signals and resultant safety-related label changes. Among 458 newly approved products, 300 were the subjects of a scheduled analysis; a new safety signal that resulted in a safety-related label change was found for 11 of these products. Less than 2% of 713 safety-related label changes were based on the scheduled analyses. Our study suggests that the safety summary analyses provide only marginal value over other pharmacovigilance activities.
Subject(s)
Adverse Drug Reaction Reporting Systems , Drug Labeling , Drug and Narcotic Control , Drug-Related Side Effects and Adverse Reactions/epidemiology , Product Surveillance, Postmarketing , Biological Products/administration & dosage , Biological Products/adverse effects , Drug Approval , Humans , United States , United States Food and Drug AdministrationABSTRACT
In May 2008, the Department of Health and Human Services announced the launch of the Sentinel Initiative by the US Food and Drug Administration (FDA) to create the Sentinel System, a national electronic system for medical product safety surveillance. This system complements existing FDA surveillance capabilities that track adverse events reported after the use of FDA regulated products by allowing the FDA to proactively assess the safety of these products.
Subject(s)
Product Surveillance, Postmarketing , United States Food and Drug Administration/legislation & jurisprudence , Adverse Drug Reaction Reporting Systems , Equipment and Supplies/adverse effects , Equipment and Supplies/standards , Humans , Pharmacovigilance , United StatesABSTRACT
Spontaneous adverse event reports constitute an important source of information on previously unknown adverse reactions to marketed medicines. However, the dynamics of such reporting following generic introduction are poorly understood. Using adverse event reports on five antiepileptic drugs from the US Food and Drug Administration's Adverse Event Reporting System, we describe temporal trends in adverse event reporting before and after generic introduction, and survey the quality of product-identifying information contained therein. The majority of reports were sent by innovator drug manufacturers while few were sent by generic manufacturers, even when generics accounted for >90% of dispensed prescriptions. We manually reviewed narratives from 2,500 reports and found that the suspect product type (brand or generic) could not be determined in 84% of reports, while generic products (16%) were identified more often than brand-name products (<1%). These results suggest that pharmacovigilance stakeholders should act to promote more detailed reporting practices.
Subject(s)
Adverse Drug Reaction Reporting Systems/trends , Anticonvulsants/adverse effects , Drug Industry/trends , Drug-Related Side Effects and Adverse Reactions/epidemiology , Drugs, Generic/adverse effects , Pharmacovigilance , Practice Patterns, Physicians'/trends , United States Food and Drug Administration/trends , Drug Prescriptions , Drug Utilization Review/trends , Humans , Time Factors , United States/epidemiologyABSTRACT
The US Food and Drug Administration emphasizes the role of regulatory science in the fulfillment of its mission to promote and protect public health and foster innovation. With respect to the evaluation of drug effects in the real world, regulatory science plays an important role in drug risk assessment and management. This article discusses opportunities and challenges with population-based drug risk assessment as well as related regulatory science knowledge gaps in the following areas: (i) population-based data sources and methods to evaluate drug safety issues; (ii) evidence-based thresholds to account for uncertainty in postmarket data; (iii) approaches to optimize the integration and interpretation of evidence from different sources; and (iv) approaches to evaluate the real-world impact of regulatory decisions. Regulators should continue the ongoing dialogue with multiple stakeholders to strengthen regulatory safety science and address these and other critical knowledge gaps.
Subject(s)
Drug Industry/legislation & jurisprudence , Drug-Related Side Effects and Adverse Reactions , Government Regulation , Product Surveillance, Postmarketing/trends , Adverse Drug Reaction Reporting Systems/legislation & jurisprudence , Adverse Drug Reaction Reporting Systems/trends , Drug Industry/trends , Drug Labeling/legislation & jurisprudence , Drug Labeling/trends , Humans , Pharmacovigilance , Risk Assessment , United States , United States Food and Drug AdministrationABSTRACT
Off-label use of medicines is common. Because many off-label uses have not been carefully studied, it is important that postmarketing drug safety systems be able to identify, assess, and monitor adverse events that occur in the off-label setting. The full range of postmarketing surveillance and analysis tools can be utilized to study the adverse effects of medicines used off-label.
Subject(s)
Drug-Related Side Effects and Adverse Reactions , Off-Label Use , Adverse Drug Reaction Reporting Systems , HumansABSTRACT
The occurrence of severe adverse events such as progressive multifocal leukoencephalopathy (PML) has the potential to limit the benefits of highly efficacious medicines being developed to fulfill unmet clinical needs across therapeutic areas. Following an Expert meeting in London in July 2011 (http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/09/WC500111562.pdf), a research agenda, highlighting methodological, clinical, and communication elements, to mitigate the risk and improve the management of drug-induced PML has been agreed upon.
Subject(s)
Global Health/standards , Leukoencephalopathy, Progressive Multifocal/chemically induced , Leukoencephalopathy, Progressive Multifocal/epidemiology , Animals , Antibodies, Monoclonal, Humanized/adverse effects , Humans , Leukoencephalopathy, Progressive Multifocal/prevention & control , London , NatalizumabABSTRACT
The contemporary science of drug safety seeks not only to identify the risks associated with the use of medicines but also to quantify these risks, identify their risk factors, and assess strategies to minimize them. It monitors the use of medicines in actual practice to understand how the medical care system interacts with the intrinsic pharmacologic properties of medicines to produce the observed effects. To the extent possible, these analyses use a population-based approach that at times requires creativity and innovation. The key to effective safety management of drugs in the postmarketing setting is the ability to access sufficient good-quality data, interpret the data appropriately, challenge old assumptions, and define best practices in contemporary drug safety approaches.
Subject(s)
Drug-Related Side Effects and Adverse Reactions , Product Surveillance, Postmarketing/methods , Drug Monitoring , Humans , Product Surveillance, Postmarketing/standards , Risk Assessment , Risk Factors , Risk Management , Statistics as Topic , Substance-Related Disorders , United States , United States Food and Drug AdministrationABSTRACT
INTRODUCTION: Human immunodeficiency virus (HIV) infection is associated with several central nervous system (CNS) infections and neoplasms. These opportunistic processes generally occur with advanced immunosuppression, but if an accurate diagnosis is made, effective treatment can frequently be initiated. METHODS: In an attempt to assess the safety, diagnostic yield, and utility of stereotactic brain biopsy in the clinical management of suspected HIV-associated primary CNS lymphoma, we retrospectively studied the performance of biopsy in HIV-seropositive patients presenting with focal intracranial lesions. This analysis included 435 patients undergoing brain biopsy, identified through a local case series (n=47) combined with all published cases (n=388). The years of analysis for this study were 1984 and 1997. We also assessed the survival of HIV-associated intracranial mass lesions and of PCNSL patients treated at JHU. RESULTS: Definitive histopathological diagnoses were established in eighty-eight percent of biopsied cases: primary CNS lymphoma (PCNSL) (30%), CNS toxoplasmosis (CNS TOXO) (16%), progressive multifocal leukoencephalopathy (PML) (25%), and other specific diagnoses (17%). Post-biopsy morbidity within thirty days was 8.4% and mortality was 2.9%. PCNSL was the most common diagnosis among cases biopsied after failure of anti-toxoplasmosis therapy, 134/205 (65%). In the local case series, biopsy-related morbidity was associated with poor functional status, decreased platelet count, and number of lesions at presentation. The median survival of irradiated PCNSL cases was 29 days longer than untreated cases (median survival 50 days versus 21 days, respectively, Chi-square=6.73, P<0.01). DISCUSSION: Stereotactic brain biopsy had a high diagnostic yield for HIV-associated focal intracranial lesions, however, the biopsy complication rate in this patient population was relatively high. PCNSL was diagnosed in the majority of patients failing anti-toxoplasmosis therapy. Survival after irradiation for PCNSL remains very poor.
Subject(s)
AIDS Dementia Complex/complications , AIDS Dementia Complex/pathology , Brain/pathology , HIV Seropositivity/pathology , Lymphoma, AIDS-Related/pathology , AIDS Dementia Complex/mortality , Follow-Up Studies , HIV Seropositivity/complications , Humans , Lymphoma, AIDS-Related/complications , Lymphoma, AIDS-Related/mortality , Lymphoma, AIDS-Related/radiotherapy , Morbidity , Retrospective Studies , Survival Analysis , Time FactorsABSTRACT
BACKGROUND: Painful sensory neuropathy is a common complication of HIV infection. Based on prior uncontrolled observations, we hypothesized that amitriptyline or mexiletine would improve the pain symptoms. METHOD: A randomized, double-blind, 10-week trial of 145 patients assigned equally to amitriptyline, mexiletine, or matching placebo. The primary outcome measure was the change in pain intensity between baseline and the final visit. RESULTS: The improvement in amitriptyline group (0.31+/-0.31 units [mean+/-SD]) and mexiletine group (0.23+/-0.41) was not significantly different from placebo (0.20+/-0.30). Both interventions were generally well tolerated. CONCLUSIONS: Neither amitriptyline nor mexiletine provide significant pain relief in patients with HIV-associated painful sensory neuropathy.
Subject(s)
Adrenergic Uptake Inhibitors/administration & dosage , Amitriptyline/administration & dosage , Anti-Arrhythmia Agents/administration & dosage , HIV Infections/complications , Mexiletine/administration & dosage , Pain/drug therapy , Adult , Double-Blind Method , Drug Therapy, Combination , Female , Follow-Up Studies , Humans , Male , Neuritis/complications , Neuritis/virology , Pain/virology , Peripheral Nerves/virologyABSTRACT
A consecutive series of 71 patients diagnosed with HIV-associated dementia (HAD) (1984-1994) were studied to characterize the clinical course of HAD, and to identify predictive markers of rapid neurologic progression. Neurologic progression rate was determined from the change in the Memorial Sloan Kettering (MSK) dementia severity score from diagnosis to death. Those with the most rapid progression in neurologic disability were compared with those with slow or no progression. Autopsy material was immunostained for macrophage activation markers and gp41 in 30 individuals. Median survival was 3.3 months and 6.1 months for rapid-progression and no-progression patients, respectively. Rapid progression was associated with injection drug use but not with race, gender, or age. CD4+ cell counts were lower at diagnosis among rapid-progression than no-progression patients but no differences in AIDS-defining illnesses or patterns of antiretroviral therapy were found. At presentation, rapid-progression patients had more prominent symptoms of mental slowing than those with no progression; however, no other clinical features, CSF, or imaging features distinguished the groups. Less abundant macrophage activation in both basal ganglia and midfrontal gyrus regions, as judged by HAM56 immunostaining, was noted in 9 no-progression patients, compared with 12 rapid-progression patients. Neurologic progression and survival with HAD is highly variable. A significant proportion of individuals with dementia have prolonged survival of more than 12 months and remain cognitively stable. A history of injection drug use and presentation with prominent psychomotor slowing is associated with more rapid neurologic progression, and these patients tend to show more abundant macrophage activation within the CNS.
Subject(s)
AIDS Dementia Complex/psychology , AIDS Dementia Complex/classification , AIDS Dementia Complex/physiopathology , Adult , Cognition/physiology , Disease Progression , Female , HIV Infections/etiology , Humans , Male , Middle Aged , Psychomotor Performance/physiology , Risk Factors , Substance Abuse, Intravenous/complications , Survival AnalysisABSTRACT
UNLABELLED: A retrospective chart review was conducted to determine the effect of alpha-Interferon (alpha-IFN) on disease progression, symptom palliation, and survival in HIV-associated Progressive Multifocal Leukoencephalopathy (PML). METHODS: Subjects were HIV seropositive patients diagnosed with PML at the Johns Hopkins Hospital between 1985 and July of 1986. Diagnostic criteria for PML included both clinical symptomatology and histologic or radiographic confirmation. All patients with concomitant CNS infections were excluded. Patients receiving a minimum treatment of 3 weeks of 3 million units of alpha-IFN daily were compared to untreated historical controls. From 104 PML cases reviewed, 77 met the defined criteria for PML. Twenty-one patients had received open-label alpha-IFN treatment in a non-randomized manner for at least 3 weeks, and 32 met criteria for inclusion in the untreated group as historical controls. Deceased treated patients were comparable to deceased untreated patients with respect to age, gender, race, HIV risk factors, AIDS-defining illnesses, and CD4+ counts. CD4+ counts and use of anti-retroviral medications within 6 months of PML onset were higher among those who were living at the time of the study. RESULTS: Among deceased patients, median survival of treated patients was 127.5 days longer than that of untreated patients (Chi-square=4.21, P=0.04). When living and deceased treated patients were combined, the median survival was 325 days (range 35 - 1634) versus 121 days (range 46 - 176) in untreated patients (Chi-square=13.47, P < 0.001). When survival times in untreated patients were left-censored to account for possible survivorship bias in treated patients, survival in treated patients remained significantly prolonged (325 days versus 175.5 days, Chi-square=4.65, P=0.03). In addition, use of alpha-IFN was associated with a significant delay in the onset of memory loss (Chi-square=8.59, P < 0.01). Seven alpha-IFN treated patients showed sustained remissions of several months to over a year, with documented improvements in mental status, aphasia, dysarthria, dysphagia, paresis, and dyscoordination. Moreover, four IFN-treated patients had evidence of MRI lesion regression, although this was not always correlated with clinical remission. Four of 32 untreated patients also reported transient symptomatic improvements. CONCLUSION: This open-label study suggests that alpha-IFN may delay progression, palliate symptoms, and significantly prolong survival in HIV-associated PML, and we therefore suggest that a controlled clinical trial is warranted.
Subject(s)
AIDS-Related Opportunistic Infections/mortality , Interferon-alpha/therapeutic use , Leukoencephalopathy, Progressive Multifocal , AIDS-Related Opportunistic Infections/diagnosis , AIDS-Related Opportunistic Infections/therapy , Adult , Disease Progression , Female , Humans , Leukoencephalopathy, Progressive Multifocal/mortality , Leukoencephalopathy, Progressive Multifocal/therapy , Leukoencephalopathy, Progressive Multifocal/virology , Magnetic Resonance Imaging , Male , Middle Aged , Recombinant Proteins/therapeutic use , Retrospective Studies , Survival AnalysisABSTRACT
To determine the clinical and virological correlates of neuropsychological test performance decline in HIV infection, we measured viral burden in blood in 272 HIV-seropositive men without dementia in the Baltimore arm of the Multicenter AIDS Cohort Study (MACS). These measures were then related to neuropsychological (NP) decline, defined as a decline relative to prior best performance of 2.0 standard deviations or more on one or more neuropsychological tests. A short battery of NP tests (Mini-Screen Battery) was administered to all 272 men. NP test performance decline was identified in 53/272 (19.5%) of participants on the Mini-Screen Battery. Follow-up NP data were available for 204 participants who had undergone the Mini-Screen. The frequency of sustained NP test performance decline was 7.8% for the Mini-Screen Battery. A lower CD4+ cell count was weakly associated with sustained NP test performance decline. After adjustment for CD4+ cell count, hemoglobin, body mass index, and presence of AIDS, none of the viral burden measures (p24 antigenemia, plasma viremia, quantitative culture) correlated with sustained NP test performance decline. We conclude that these measures of blood HIV viral burden are not markers for NP decline, but that a lower CD4+ cell count is.
Subject(s)
AIDS Dementia Complex/immunology , AIDS Dementia Complex/virology , HIV Core Protein p24/blood , Viremia/immunology , Viremia/virology , AIDS Dementia Complex/drug therapy , Adult , Antiviral Agents/administration & dosage , CD4 Lymphocyte Count , CD4-Positive T-Lymphocytes , HIV Core Protein p24/isolation & purification , HIV-1 , Humans , Longitudinal Studies , Male , Middle Aged , Viremia/drug therapy , Zidovudine/administration & dosageABSTRACT
OBJECTIVES: To determine the impact of neurologic disease on length of stay and total hospital charges for hospitalizations related to human immunodeficiency virus (HIV) infection. DESIGN: Review of all HIV-related hospitalizations from all acute nonfederal hospitals in Maryland in 1991 and 1992. Neurologic status and HIV disease status were determined by codes from the International Classification of Diseases, Ninth Revision Clinical Modification, in an administrative database. Total hospital charges and length of stay were also included in this database. RESULTS: Of 12 128 HIV-related hospitalizations (6013 patients with the acquired immunodeficiency syndrome [AIDS], 308 HIV-seropositive patients with symptoms without AIDS, and 5807 HIV-seropositive patients without symptoms), neurologic disease occurred in 1013 (8.4%), predominantly in patients with AIDS. In all HIV-seropositive patients, those with primary neurologic disease had a long mean (+/- SD) length of stay (16.4 +/- 16.5 days vs 9.3 +/- 11.3 days; P < .001) and higher mean (+/- SD) total charges ($12,733 +/- $12,009 vs $8069 +/- $11,247; P < .001) than those without neurologic disease. In patients with AIDS, those with primary neurologic disease also had a longer mean (+/- SD) length of stay (17.2 +/- 17.2 days vs 11.7 +/- 12.7 days; P < .001) and higher mean (+/- SD) total charges ($13,430 +/- $12,470 vs $10,794 +/- $13,537; P < .001) than those without neurologic disease. After adjustment for age, sex, race, and stage of HIV infection in all HIV-seropositive patients, our results indicated that neurologic disease increased the length of stay by 3.3 days (95% confidence interval [CI], 2.9-3.8) and total charges by $2552 (95% CI, $2111-$2993). After adjustment for age, sex, and race in discharged patients with AIDS, the results showed that neurologic disease increased length of stay by 2.24 days (95% CI, 0.73-3.77) and total charges by $1512 (95% CI, $40-$2894). CONCLUSION: Neurologic disease increases the length of stay and total hospital charges of HIV-infected patients.
Subject(s)
HIV Infections/complications , Hospitalization/statistics & numerical data , Hospitals/statistics & numerical data , Nervous System Diseases/epidemiology , Acquired Immunodeficiency Syndrome/complications , Acquired Immunodeficiency Syndrome/economics , Adult , Female , HIV Infections/economics , HIV Seropositivity/economics , Health Care Surveys , Hospital Charges/statistics & numerical data , Hospitalization/economics , Humans , Length of Stay/economics , Length of Stay/statistics & numerical data , Male , Maryland/epidemiology , Middle Aged , Nervous System Diseases/economics , Nervous System Diseases/etiology , Utilization ReviewABSTRACT
The objective of this study was to determine if sustained decline in psychomotor speed tests is associated with an increased risk of progression to dementia, acquired immunodeficiency syndrome (AIDS), or mortality in human immunodeficiency virus (HIV)-1-infected homosexual men in the Baltimore site of the Multicenter AIDS Cohort-Study (MACS). Clinical and neuropsychological data were obtained on 291 HIV+ homosexual men seen semi-annually over a nine year period (1986-1994). A proportional hazards model was used to assess the predictive value of sustained psychomotor slowing (defined as a 2.0 standard deviation (s.d.) decline in performance on either the Symbol Digit Modalities test or Trailmaking test at two consecutive evaluations). Time-dependent co-variates included in the model were sustained psychomotor slowing, number of attended visits, CD4+ lymphocyte count, hemoglobin and antiretroviral medication use. HIV+ participants with and without sustained psychomotor slowing were compared. Outcome variables were the development of dementia, AIDS and death. HIV+ subjects with sustained psychomotor slowing had an increased hazard of dementia (Risk ratio (RR) = 5.0, P = 0.008), AIDS (RR = 2.4, P = 0.02), and death (RR = 2.0, P = 0.04). A similar analysis using sustained cognitive decline in one domain from a more extensive neuropsychological test battery failed to show any predictive value. Sustained decline in psychomotor performance in HIV infection was predictive of dementia, AIDS and death. This brief neuropsychological test battery may be useful for early detection of HIV+ individuals with a poorer prognosis who may benefit from more aggressive treatment to prevent HIV dementia.
Subject(s)
AIDS Dementia Complex/mortality , Acquired Immunodeficiency Syndrome/mortality , HIV Infections/complications , Psychomotor Disorders/virology , Acquired Immunodeficiency Syndrome/psychology , Acquired Immunodeficiency Syndrome/therapy , Adult , Cognition Disorders/diagnosis , Cognition Disorders/virology , Cohort Studies , Demography , HIV Infections/psychology , HIV Infections/therapy , Humans , Longitudinal Studies , Male , Neuropsychological Tests , Predictive Value of Tests , Prognosis , Psychomotor Disorders/diagnosis , Risk Factors , Treatment OutcomeABSTRACT
There are a variety of HIV-related neurologic complications that have numerous causes. HIV-related neurologic illnesses are specific to the stage of HIV infection, although the greatest burden of neurologic disease and the most disabling syndromes occur in the more advanced stages. As the number of HIV-infected persons continues to increase worldwide and as antiretroviral and other anti-infective therapies improve patient survival in the advanced stages of HIV infection, the burden of neurologic disease will continue to increase.
Subject(s)
HIV Infections/epidemiology , Nervous System Diseases/epidemiology , AIDS Dementia Complex/epidemiology , AIDS-Related Opportunistic Infections/complications , AIDS-Related Opportunistic Infections/epidemiology , Adolescent , Adult , Age Distribution , Antiviral Agents/adverse effects , Child , Disease Progression , Female , Global Health , HIV Infections/complications , HIV Infections/transmission , Humans , Incidence , Infant, Newborn , Lymphoma, AIDS-Related/epidemiology , Lymphoma, AIDS-Related/etiology , Male , Nervous System Diseases/etiology , Neuromuscular Diseases/complications , Neuromuscular Diseases/epidemiology , Neuromuscular Diseases/etiology , Paraparesis, Tropical Spastic/complications , Paraparesis, Tropical Spastic/epidemiology , Paraparesis, Tropical Spastic/etiology , Prevalence , Risk Factors , Sex DistributionABSTRACT
We studied the features and frequency of sensory neuropathy among 79 HIV-1-infected individuals participating in a multicenter clinical trial of zalcitabine (2'3'-dideoxycytidine, or ddC) antiretroviral therapy. The trial compared zalcitabine monotherapy (2.25 mg/day) versus combination therapy (2.25 mg/day ddC) with zidovudine (ZDV, formerly AZT) versus monotherapy with ZDV alone. Neuropathy developed in 34% of ddC recipients but in only 4% of comparable patients treated with ZDV alone--a 7.9-fold increase in the attack rate of neuropathy. Using risk factor analysis, we found that diabetes mellitus was significantly associated with the development of toxic neuropathy (p = 0.02), and weight loss may contribute to its appearance. Like HIV-associated sensory neuropathy, ddC-related toxic neuropathy is a predominantly sensory, length-dependent, symmetric, painful neuropathy. Dose reduction lessened the severity of symptoms, although objective signs of neuropathy persisted. Patients with subclinical neuropathies or significant neuropathy risks such as diabetes may be poor candidates for ddC therapy.
Subject(s)
Nervous System Diseases/chemically induced , Sensation Disorders/chemically induced , Zalcitabine/administration & dosage , Zalcitabine/adverse effects , Adult , Cohort Studies , Dose-Response Relationship, Drug , Double-Blind Method , Female , HIV Seropositivity/drug therapy , Humans , Incidence , Male , Middle Aged , Nervous System Diseases/epidemiology , Nervous System Diseases/physiopathology , Risk Factors , Sensation Disorders/epidemiology , Sensation Disorders/physiopathology , Survival Analysis , Zalcitabine/therapeutic useABSTRACT
To determine the clinical correlates of HIV-1-associated vacuolar myelopathy (VM), we designed a case-control study based on 215 AIDS autopsies in which we examined the spinal cord. We defined a case as an individual dying with AIDS and with VM present at autopsy; we defined a control as an individual dying with AIDS without VM. VM was found in 100 of 215 (46.5%) autopsies, with no apparent temporal trends. A higher number of AIDS-defining illnesses was strongly associated with the likelihood of VM (trend chi-square = 26.52, p < 0.001). Systemic infection with Mycobacterium avium-intracellulare and Pneumocystis carinii pneumonia were each associated with the pathologic findings of VM in both univariate and multivariate models. In the brain, multinucleated giant cells were detected in more cases than in controls (odds ratio = 3.68, 95% CI = 1.73 to 7.47, p < 0.001). The clinical features of HIV-1 dementia were not associated with VM; in contrast, predominantly sensory neuropathy was more common in VM cases than in controls (odds ratio = 5.00, 95% CI = 1.35 to 18.5, p < 0.05). Fifty-six cases with VM had detailed neurologic evaluations, but only 15 (26.8%) had signs and symptoms of myelopathy. The presence of symptomatic myelopathy was related to the pathologic severity: none of 17 cases with grade 1, five of 26 with grade 2, and 10 of 13 with grade 3 had clinical features of myelopathy (trend chi-square = 21.16, p < 0.005). VM is a common neuropathologic finding that is frequently unrecognized during life. The association with the number of systemic illnesses, M avium-intracellulare infection, and P carinii pneumonia suggests that the development of VM is related to the severity of immunosuppression.
Subject(s)
HIV Infections/etiology , HIV Infections/pathology , HIV-1 , Spinal Cord Diseases/etiology , Spinal Cord Diseases/pathology , AIDS-Related Opportunistic Infections/epidemiology , AIDS-Related Opportunistic Infections/etiology , AIDS-Related Opportunistic Infections/pathology , Adult , Case-Control Studies , Confidence Intervals , Female , HIV Infections/epidemiology , Humans , Male , Middle Aged , Odds Ratio , Spinal Cord Diseases/epidemiology , Vacuoles/pathologyABSTRACT
Quantified magnetic resonance imaging (MRI) was related to neuropsychological (NP) test scores in an asymptomatic HIV-1 seropositive group, a non-demented AIDS/ARC group, a group of subjects with HIV-1 dementia, and a seronegative control group. The MRIs were quantified using three planimetric measures of brain structure: the bicaudate ratio (a measure of caudate region atrophy), the bifrontal ratio (a measure of frontal region atrophy), and the ventricle to brain ratio (a measure of overall cerebral atrophy). Cognitive performance was assessed with standard NP tests. Significant correlations between the MRI ratios and many of the NP tests were observed. Of the tests grooved pegboard, part B of the trail making test, the verbal fluency test, and the digit span forward were associated with MRI abnormalities. The bicaudate ratio was most closely associated with the NP tests. These findings indicate that ventricular enlargement, especially in the region of the caudate, is closely related to poor NP test performance in HIV-1 infection.
Subject(s)
Acquired Immunodeficiency Syndrome/physiopathology , Brain Diseases/physiopathology , Brain/physiopathology , Acquired Immunodeficiency Syndrome/complications , Adult , Brain/diagnostic imaging , Brain Diseases/diagnosis , Brain Diseases/etiology , Caudate Nucleus/diagnostic imaging , Caudate Nucleus/physiopathology , Cerebral Ventricles/physiopathology , Cognition Disorders/diagnosis , Cognition Disorders/etiology , Cognition Disorders/physiopathology , HIV Seropositivity , HIV-1 , Humans , Magnetic Resonance Imaging , Male , Neuropsychological Tests , RadiographyABSTRACT
Cerebral atrophy is a common radiologic manifestation of HIV dementia. To evaluate the relationship between cognitive impairment and cerebral atrophy, adjusting for age and immune status, we used standardized planimetry to measure the ventricle-brain ratio (VBR) and the bifrontal (BFR) and bicaudate (BCR) ratios, three measures of cerebral atrophy. We analyzed cranial MRIs of 23 HIV-1-seronegative controls (SN) and 116 HIV-1-infected individuals. Of the HIV-1-seropositive individuals, 37 had HIV dementia (DM group), 40 had neurologic or neuropsychological abnormalities insufficient for HIV dementia (NP+ group), and 39 were neurologically normal (NML group). We performed comparisons using analysis of covariance with correction for multiple comparisons. Both the VBR, a general measure of overall cerebral atrophy, and the BCR, a measure of atrophy in the region of the caudate nucleus, are significantly associated with dementia. The association is stronger for BCR enlargement than for VBR enlargement, suggesting that selective caudate region atrophy is associated with HIV dementia. These results indicate that overall cerebral atrophy and prominent caudate region atrophy are important radiographic features of HIV dementia.
Subject(s)
Brain/pathology , HIV Infections/pathology , HIV-1 , AIDS Dementia Complex/pathology , Acquired Immunodeficiency Syndrome/pathology , Adult , Analysis of Variance , Atrophy/pathology , Cerebral Ventricles/pathology , Female , Humans , Magnetic Resonance Imaging , Male , Middle AgedABSTRACT
Clock-drawing is a widely used bedside test of constructional ability, but it has never been systematically studied or standardized. We examined 87 clocks drawn by neurologically impaired patients and age-matched controls, and propose a set of criteria for scoring clocks. Patients with probable Alzheimer's disease and other dementias have gross impairments in clock-drawing. These deficits include poor spatial arrangement of numbers, incorrect numerical sequence, insertion of stray lines, and addition of extra numbers. In Alzheimer's disease, the total score on the clock-drawing test correlates with the score on the Modified "Mini-Mental State" Examination. Non-demented patients with Parkinson's disease showed only defects in the spatial organization of the numbers, and non-demented patients with other diseases perform as well as controls.